Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.54+0.01 (+2.72%)
Close on Nov 17, 2026Market cap $2.26MP/E –Yield –
Valion Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Valion Bio's operating income for the twelve months ending Jun 30, 2026 was -$16.52M. For fiscal 2025 it was -$7.90M. The highest annual figure on record is -$4.48M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.90M | – |
| FY2024 | Dec 31, 2024 | -$4.48M | – |
| FY2023 | Dec 31, 2023 | -$8.25M | – |
| FY2022 | Dec 31, 2022 | -$10.10M | – |
| FY2021 | Dec 31, 2021 | -$5.63M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$298.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.43M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.02M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.24M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.29M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.06M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.06M | – |
See a number that looks wrong?